Reward-potentiating effects of D-1 dopamine receptor agonist and AMPAR GluR1 antagonist in nucleus accumbens shell and their modulation by food restriction.
BACKGROUND
Previous studies have suggested that chronic food restriction (FR) increases sensitivity of a neural substrate for drug reward. The neuroanatomical site(s) of key neuroadaptations may include nucleus accumbens (NAc) where changes in D-1 dopamine (DA) receptor-mediated cell signaling and gene expression have been documented.


OBJECTIVE
The purpose of the present study was to begin bridging the behavioral and tissue studies by microinjecting drugs directly into NAc medial shell and assessing behavioral effects in free-feeding and FR subjects.


METHODS
Rats were implanted with microinjection cannulae in NAc medial shell and a subset were implanted with a stimulating electrode in lateral hypothalamus. Reward-potentiating effects of the D-1 DA receptor agonist, SKF-82958, AMPAR antagonist, DNXQ, and polyamine GluR1 antagonist, 1-na spermine, were assessed using the curve-shift method of self-stimulation testing. Motor-activating effects of SKF-82958 were also assessed.


RESULTS
SKF-82958 (2.0 and 5.0 microg) produced greater reward-potentiating and motor-activating effects in FR than ad libitum fed (AL) rats. DNQX (1.0 microg) and 1-na spermine (1.0 and 2.5 microg) selectively decreased the x-axis intercept of rate-frequency curves in FR subjects, reflecting increased responding for previously subthreshold stimulation.


CONCLUSIONS
Results suggest that FR may facilitate reward-directed behavior via multiple neuroadaptations in NAc medial shell including upregulation of D-1 DA receptor function involved in the selection and expression of goal-directed behavior, and increased GluR1-mediated activation of cells that inhibit nonreinforced responses.
Carr
Kenneth D
KD
Department of Psychiatry, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA. kc16@nyu.edu
Cabeza de Vaca
Soledad
S
Sun
Yanjie
Y
Chau
Lily S
LS
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000494:pharmacology*; D004558:Electric Stimulation; D004567:Electrodes, Implanted; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D005508:Food Deprivation / Q000502:physiology*; D015870:Gene Expression / Q000187:drug effects; D008297:Male; D008845:Microinjections; D009043:Motor Activity / Q000187:drug effects; D009714:Nucleus Accumbens / Q000502:physiology*; D011810:Quinoxalines / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors*; D017447:Receptors, Dopamine D1 / Q000819:agonists* / Q000235:genetics; D012201:Reward; D012653:Self Stimulation; D013096:Spermine / Q000031:analogs & derivatives* / Q000494:pharmacology
D001552:Benzazepines; D018491:Dopamine Agonists; D018691:Excitatory Amino Acid Antagonists; D011810:Quinoxalines; D018091:Receptors, AMPA; D017447:Receptors, Dopamine D1; D013096:Spermine; C067506:1-naphthylacetylspermine; C056723:FG 9041; C071262:SK&F 82958